ArticleJAMA neurology2024
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage.
Article in JAMA neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- Machine learning versus conventional methods for prehospital detection of stroke due to large vessel occlusion or intracranial haemorrhage.European stroke journal · 2026Article
- Effect on Mortality of Anticoagulant Reversal in Acute Intracranial Hemorrhage: A Systematic Review and Meta-analysis.Neurocritical care · 2026Article
- Development and Validation of a Machine Learning Model to Predict Oral Anticoagulant Use in Stroke From Prothrombin Time-International Normalized Ratio and Activated Partial Thromboplastin Time.Journal of the American Heart Association · 2026Article
- Beating the clock: comparing the speed of anticoagulation reversal in intracerebral haemorrhage to thrombolysis for acute ischaemic stroke.European stroke journal · 2026Article
- The incidence and impact of early post-stroke seizures for successful endovascular stroke treatment: an individual patient data level analysis of trials.International journal of surgery (London, England) · 2026Article
- Accelerating Reversal and Refining Transfer Are Imperative for Anticoagulation-Associated Intracerebral Hemorrhage.Journal of the American Heart Association · 2026Article
- Timeliness of Care for Transferred and Directly Admitted Patients With Anticoagulation-Associated Intracerebral Hemorrhage.Journal of the American Heart Association · 2026Article
- Factors associated with hematoma expansion in deep versus lobar intracerebral haemorrhage: a multicentre observational study.European stroke journal · 2026Observational
- Reversing Anticoagulants: Influence of Anticoagulation Stewardship and Key Considerations for Optimizing Outcomes.The Annals of pharmacotherapy · 2026Article
- Code Intracerebral Hemorrhage: A Quality Improvement Pilot Study.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Incidence and outcomes of major bleeding among first-time oral factor Xa inhibitor users: multinational observational cohort studies.Research and practice in thrombosis and haemostasis · 2026Article
- Atypical Hemorrhagic Presentation of Neurocysticercosis in a Patient on Chronic Anticoagulation.Cureus · 2026Article
- Four-Factor Prothrombin Complex Concentrate Administration Timing in Oral Anticoagulant-Associated Intracranial Hemorrhage.Hospital pharmacy · 2026Article
- Risk factors and development of a prediction model for hematoma expansion in elderly patients with spontaneous intracerebral hemorrhage.Frontiers in aging neuroscience · 2026Article
- Recent research progress and future directions of intracerebral hemorrhage.Frontiers in immunology · 2026Review
- Anticoagulation associated intracerebral haemorrhage trends, treatment and outcomes in a metropolitan cohort: analysed by availability of specific versus non-specific reversal agents.BMJ neurology open · 2026Article
- Review
- Emergency Reversal of Antithrombotics in Intracerebral Hemorrhage: An Update.Current neurology and neuroscience reports · 2025Review
- Review
- Intracerebral Hemorrhage in Aging: Pathophysiology, Clinical Challenges, and Future Directions.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 11 institutions in 2 countries.
Funding
Abstract
Importance: Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether there is a time-dependent treatment effect for door-to-treatment (DTT) times in clinical practice. Objective: To evaluate whether DTT time is associated with outcome among patients with anticoagulation-associated ICH treated with reversal interventions. Design, Setting, and Participants: This cohort study used data from the American Heart Association Get With The Guidelines-Stroke quality improvement registry. Patients with ICH who presented within 24 hours of symptom onset across 465 US hospitals from 2015 to 2021 were included. Data were analyzed from January to September 2023. Exposures: Anticoagulation-associated ICH. Main Outcomes and Measures: DTT times and outcomes were analyzed using logistic regression modeling, adjusted for demographic, history, baseline, and hospital characteristics, with hospital-specific random intercepts to account for clustering by site. The primary outcome of interest was the composite inpatient mortality and discharge to hospice. Additional prespecified secondary outcomes, including functional outcome (discharge modified Rankin Scale score, ambulatory status, and discharge venue), were also examined. Results: Of 9492 patients with anticoagulation-associated ICH and documented reversal intervention status, 4232 (44.6%) were female, and the median (IQR) age was 77 (68-84) years. A total of 7469 (78.7%) received reversal therapy, including 4616 of 5429 (85.0%) taking warfarin and 2856 of 4069 (70.2%) taking a non-vitamin K antagonist oral anticoagulant. For the 5224 patients taking a reversal intervention with documented workflow times, the median (IQR) onset-to-treatment time was 232 (142-482) minutes and the median (IQR) DTT time was 82 (58-117) minutes, with a DTT time of 60 minutes or less in 1449 (27.7%). A DTT time of 60 minutes or less was associated with decreased mortality and discharge to hospice (adjusted odds ratio, 0.82; 95% CI, 0.69-0.99) but no difference in functional outcome (ie, a modified Rankin Scale score of 0 to 3; adjusted odds ratio, 0.91; 95% CI, 0.67-1.24). Factors associated with a DTT time of 60 minutes or less included White race, higher systolic blood pressure, and lower stroke severity. Conclusions and Relevance: In US hospitals participating in Get With The Guidelines-Stroke, earlier anticoagulation reversal was associated with improved survival for patients with ICH. These findings support intensive efforts to accelerate evaluation and treatment for patients with this devastating form of stroke.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.